Novocure Limited (NVCR)
Stock Price:
$123.77 USD
-1.27 (-1.02%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed
After-hours: $120.15 -3.62 (-2.93%) Oct 23, 7:50 PM
Key Info
| Market Cap |
12.51B |
| Revenue (ttm) |
409.05M |
| Net Income (ttm) |
11.80M |
| Shares Out |
101.09M |
| EPS (ttm) |
0.11 |
| PE Ratio |
1,125.18 |
| Forward PE |
312.50 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 23, 2020 |
| Last Price |
$123.77 |
| Previous Close |
$125.04 |
| Change ($) |
-1.27 |
| Change (%) |
-1.02% |
| Day's Open |
125.59 |
| Day's Range |
121.73 - 127.48 |
| Day's Volume |
736,625 |
| 52-Week Range |
53.40 - 140.89 |
More Stats
| Market Cap |
12.51B |
| Enterprise Value |
12.33B |
| Earnings Date (est) |
Oct 28, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
101.09M |
| Float |
83.59M |
| EPS (basic) |
0.13 |
| EPS (diluted) |
0.11 |
| FCF / Share |
0.24 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
0.09% |
| FCF Yield |
0.19% |
| Payout Ratio |
n/a |
| Shares Short |
5.33M |
| Short Ratio |
3.80 |
| Short % of Float |
6.38% |
| Beta |
1.40 |
| PE Ratio |
1,125.18 |
| Forward PE |
312.50 |
| P/FCF Ratio |
513.27 |
| PS Ratio |
30.59 |
| PB Ratio |
47.20 |
| Revenue |
409.05M |
| Operating Income |
7.30M |
| Net Income |
11.80M |
| Free Cash Flow |
24.38M |
| Net Cash |
184.34M |
| Net Cash / Share |
1.82 |
| Gross Margin |
64.31% |
| Operating Margin |
1.78% |
| Profit Margin |
2.90% |
| FCF Margin |
5.96% |
| ROA |
1.02% |
| ROE |
5.53% |
| ROIC |
1.90% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (9)
| Buy |
3 |
| Overweight |
0 |
| Hold |
5 |
| Underweight |
0 |
| Sell |
1 |
Analyst Consensus: Overweight
Price Target
$108.00*
(-12.74% downside)
Low
75.0
Current: $123.77
High
200.0
Target: 108.00
*Average 12-month price target from 8 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|
| Revenue | 351 | 248 | 177 | 82.89 | 33.09 | 15.49 | 10.36 |
| Revenue Growth | 41.62% | 40.13% | 113.57% | 150.52% | 113.6% | 49.53% | - |
| Gross Profit | 263 | 168 | 121 | 36.61 | 12.48 | 5.45 | 3.35 |
| Operating Income | -0.91 | -33.67 | -39.33 | -115 | -104 | -80.16 | -64.46 |
| Net Income | -7.23 | -63.56 | -61.66 | -132 | -112 | -80.68 | -77.37 |
| Shares Outstanding | 97.24 | 91.83 | 88.55 | 85.56 | 30.40 | 12.49 | 11.50 |
| Earnings Per Share | -0.07 | -0.69 | -0.70 | -1.54 | -3.67 | -6.46 | -6.73 |
| Operating Cash Flow | 26.62 | -1.87 | -33.13 | -108 | -99.88 | -74.24 | -52.72 |
| Capital Expenditures | -10.49 | -6.71 | -7.37 | -17.66 | -10.27 | -2.32 | -3.63 |
| Free Cash Flow | 16.14 | -8.58 | -40.50 | -125 | -110 | -76.56 | -56.34 |
| Cash & Equivalents | 328 | 248 | 185 | 220 | 270 | 103 | 177 |
| Total Debt | 164 | 149 | 97.34 | 96.23 | 23.10 | - | - |
| Net Cash / Debt | 165 | 98.74 | 88.10 | 124 | 246 | 103 | 177 |
| Assets | 479 | 340 | 265 | 282 | 307 | 118 | 189 |
| Liabilities | 262 | 228 | 152 | 140 | 56.52 | 20.00 | 17.13 |
| Book Value | 218 | 112 | 114 | 142 | 251 | 97.88 | 172 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Novocure Limited |
| Country |
United Kingdom |
| Employees |
782 |
| CEO |
Asaf Danziger |
Stock Information
| Ticker Symbol |
NVCR |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Medical Instruments & Supplies |
| Unique Identifier |
NASDAQ: NVCR |
| IPO Date |
October 2, 2015 |
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and NovoTTF-100L, a Tumor Treating Fields delivery system for use as a monotherapy treatment for adult patients with glioblastoma. It is also developing products that are in Phase 2 pilot and Phase 3 pivotal trials for brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer, and mesothelioma. The company markets its products in the European Union, Japan, and internationally. It has a clinical trial collaboration agreement with MSD to evaluate tumor treating fields together with KEYTRUDA, an anti-PD-1 therapy. NovoCure Limited was founded in 2000 and is based in Saint Helier, Jersey.